Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.50 |
| ▸ | RELA | Q04206 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TOP2A | P11388 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6640584 | 0.90 | KMT2A (0.60) | NPC1RAB9ACTSBMAPTKMT2A | |
| SCHEMBL8150025 | 0.89 | CTSB (0.48) | NPC1RAB9ACTSBMAPTKMT2A | |
| SCHEMBL99844 | 0.87 | NPSR1 (0.50) | NPC1RAB9ACTSBMAPTKMT2A | |
| SCHEMBL6640190 | 0.86 | FABP4 (0.57) | NPC1RAB9ACTSBMAPTKMT2A | |
| SCHEMBL31647232 | 0.84 | APP (0.55) | NPC1RAB9AMAPTKMT2AALDH1A1 | |
| SCHEMBL27595525 | 0.83 | MAPT (0.50) | NPC1RAB9ACTSBMAPTKMT2A | |
| SCHEMBL10691068 | 0.82 | NPC1 (0.55) | NPC1RAB9ACTSBMAPTKMT2A | |
| SCHEMBL97659 | 0.81 | NPC1 (0.54) | NPC1RAB9ACTSBMAPTKMT2A | |
| SCHEMBL2479303 | 0.79 | NPC1 (0.46) | NPC1RAB9ACTSBMAPTKMT2A | |
| SCHEMBL14645731 | 0.78 | HTT (0.65) | NPC1RAB9ACTSBMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2264028-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-22 | — | — | EP | claimed |
| US-9132130-B2 | Purine derivative and antitumor agent using same | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2015-09-15 | — | — | US | disclosed |
| US-9132130-B2 | Purine derivative and antitumor agent using same | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2015-09-15 | — | — | US | disclosed |
| US-9132130-B2 | Purine derivative and antitumor agent using same | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2015-09-15 | — | — | US | disclosed |
| EP-2426130-B1 | PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME | ZENYAKU KOGYO KK (JP) | 2015-03-11 | — | — | EP | disclosed |
| US-20120088765-A1 | PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2012-04-12 | — | — | US | disclosed |
| US-20120088765-A1 | PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2012-04-12 | — | — | US | disclosed |
| US-20120088765-A1 | PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2012-04-12 | — | — | US | disclosed |
| EP-2426130-A1 | PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2012-03-07 | — | — | EP | disclosed |
| EP-1702920-B1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMA (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20030004161-A1 | Pyrazole compounds useful as protein kinase inhititors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-01-02 | — | — | US | disclosed |
| EP-1247804-A1 | Pyrimidine-thioalkyl and alkylether compounds | PHARMACIA & UPJOHN COMPANY (US) | 2002-10-09 | — | — | EP | disclosed |
| WO-2002068415-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-09-06 | — | — | WO | disclosed |
| WO-2002066461-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002062789-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-08-15 | — | — | WO | disclosed |
| WO-2002059111-A2 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002057259-A2 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002050065-A2 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-06-27 | — | — | WO | disclosed |
| US-4559345-A | Pyrimidine and s-triazine derivatives with antilipidemic activity | LBP ISTITUTO FARACEUTICO S.P.A. (IT) | 1985-12-17 | — | — | US | disclosed |
| EP-0073328-A1 | Novel pyrimidine and s. triazine derivatives with antilipidemic activity | LPB Istituto Farmaceutico s.p.a. (IT) | 1983-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004161-A1 | Pyrazole compounds useful as protein kinase inhititors | AURKC, AURKA, GSKIP | NPC1 2375/4885RAB9A 2278/4885CTSB 3627/4885 |
| US-20120088765-A1 | PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME | PNP, TYMP, DPYD | NPC1 1489/4885RAB9A 2254/4885CTSB 3481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.